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The oncogenic transcription factor signal transducer and activator of transcription 3 (STAT3) is overactivated inmalignant
glioma and plays a key role in promoting cell survival, thereby increasing the acquired apoptosis resistance of these
tumors. Here we investigated the STAT3/myeloid cell leukemia 1 (MCL1) signaling pathway as a target to overcome the
resistance of glioma cells to the Bcl-2-inhibiting synthetic BH3 mimetic ABT-737. Stable lentiviral knockdown of MCL1
sensitizedLN229andU87gliomacells to apoptotic cell death inducedby single-agent treatmentwithABT-737whichwas
associated with an early activation of DEVDase activity, cytochrome c release, and nuclear apoptosis. Similar sensitizing
effectswere observedwhenABT-737 treatmentwas combinedwith themultikinase inhibitor sorafenibwhich effectively
suppressed levels of phosphorylated STAT3 and MCL1 in MCL1-proficient LN229 and U87 glioma cells. In analogous
fashion, these synergistic effects were observed when we combined ABT-737 with the STAT3 inhibitor WP-1066.
Lentiviral knockdown of the activating transcription factor 5 combined with subsequent quantitative polymerase chain
reaction analysis revealed that sorafenib-dependent suppression ofMCL1 occurred at the transcriptional level but did not
depend on activating transcription factor 5 which previously had been proposed to be essential for MCL1-dependent
glioma cell survival. In contrast, the constitutively active STAT3mutant STAT3-Cwas able to significantly enhanceMCL1
levels under sorafenib treatment to retain cell survival. Collectively, these data demonstrate that sorafenib targets MCL1
in a STAT3-dependent manner, thereby sensitizing glioma cells to treatment with ABT-737. They also suggest that
targeting STAT3 in combinationwith inducers of the intrinsic pathway of apoptosismay be a promising novel strategy for
the treatment of malignant glioma.
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Gliomas are the most common primary brain tumors in humans.
Glioblastoma multiforme is the highest-grade, most aggressive, and
frequent glioma [1,2]. A major hallmark of malignant gliomas is their
diffuse infiltrative growth into the surrounding brain tissue which renders
complete tumor resection impossible [3]. Combined radiotherapy and
chemotherapy prolong survival of glioblastoma multiforme patients for
several months [4,5], but eradication of residual tumor cells is severely
hampered by their intrinsic apoptosis resistance [6], which significantly
contributes to the invariable manifestation of tumor recurrence.
Therefore, experimental approaches designed to reactivate cell death in
apoptosis-refractory malignant glioma have important implications for
the development of novel glioma therapies.
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transcription 3 (STAT3), a component of the Janus-activated kinase
(JAK)/STAT3 signaling pathway, is involved in a wide variety of
physiological and pathophysiological processes [7,8]. STAT3 is mainly
activated via tyrosine phosphorylation (Tyr705) by growth factor/
cytokine receptors and non–receptor tyrosine kinases, leading to STAT3
dimerization, nuclear translocation, and subsequent activation of various
STAT3 target genes that modulate cell survival, migration, invasion,
immune evasion, and angiogenesis [8]. In glioma, activation of STAT3
positively correlates with tumor malignancy [9,10] and predicts a poor
clinical outcome [11]. We and others have previously demonstrated the
essential function of STAT3 for the highly apoptosis-resistant, proinvasive
phenotype of malignant glioma in vitro and in vivo [12–16].
Pro- and antiapoptotic members of the Bcl-2 family are other key
regulators of the mitochondrial (intrinsic) pathway of apoptosis [17].
The Bcl-2 protein family is comprised of three subgroups: 1) the
proapoptotic Bax-like proteins (Bax, Bak), 2) the Bcl-2–like proteins
[Bcl-2, Bcl-xL, Bcl-W, myeloid cell leukemia 1 (MCL1)], and 3) the
proapoptotic BH3-only proteins (Bad, Bim, Bid, etc.), which serve to
couple diverse stress stimuli to the intrinsic apoptosis pathway
[17,18]. During apoptosis, Bax and Bak trigger mitochondrial outer
membrane permeabilization, which is required for the release of
proapoptotic factors from the mitochondria into the cytosol. In
nonapoptotic cells, Bax and Bak are kept in check by direct binding of
the antiapoptotic Bcl-2–like proteins [17–19].
Ever since themolecular cloning of Bcl-2 byKorsmeyer and colleagues,
there has been a tremendous interest in the role of Bcl-2 and its
homologues in drug resistance and their exploitation as drug targets [20].
Prosurvival Bcl-2 family members are known to be overexpressed in a
wide variety of human malignancies, and small molecule inhibitors of
Bcl-2–like proteins, also termed BH3mimetics, are perceived to be highly
promising anticancer drugs [21,22]. The most advanced and best
characterized synthetic Bcl-2 inhibitor is the Bad-like BH3 mimetic
ABT-737 [23] and its orally applicable derivative ABT-263 [24,25],
which is currently investigated in a number of clinical phase I/II studies
(https://clinicaltrials.gov). Structurally, the prosurvival Bcl-2 family
members can be divided into two categories. Bcl-2, Bcl-xL, and Bcl-w
are structurally closely related, whereas the accessibility of theBH3binding
pocket of MCL1 (and the less well studied Bcl-2 family member A1) is
structurally different from the other three family members. ABT-737
effectively inhibits the antiapoptotic functions of Bcl-2, Bcl-xL, andBcl-W
but fails to target MCL1 [21]. Therefore, MCL1 plays a pivotal role in
resistance to Bcl-2/Bcl-xL/Bcl-w-specific inhibitors such as ABT-737.
The multikinase inhibitor sorafenib (Nexavar, Bayer HealthCare
Pharmaceuticals, Whippany, NJ, USA) has originally been developed
as a RAF inhibitor but also targets several tyrosine kinase receptors.
Sorafenib is an orally available drug that is currently under clinical
testing in numerous trials including treatment of glioblastoma
patients. Here we demonstrate that sorafenib targets MCL1 and
efficiently synergizes with ABT-737 to trigger apoptosis in glioma
cells. Furthermore, we identify STAT3 as a key upstream regulator of
MCL1 and demonstrate the pivotal role of the STAT3/MCL1
signaling axis in apoptosis resistance of glioma.
Materials and Methods
Reagents
ABT-737, sorafenib, and WP-1066 (pStat3 inhibitor III) were
obtained from Santa Cruz, Heidelberg, Germany. z-Val-Ala-DL-Asp-fluoromethylketone was from Bachem (Weil am Rhein, Germany). Cell
culturemedium (Dulbecco’s modified Eagle’s medium) and supplements
were purchased from Invitrogen (Darmstadt, Germany). All other
biochemicals and chemicals were provided in analytical-grade purity from
Roth (Karlsruhe, Germany) or Sigma-Aldrich (Seelze, Germany).
Cell Culture and Lentiviral Transduction
All experiments were performed in the human glioma cell lines
LN229, U343, andU87 [25,26].MCL1 (SHCLNV-NM_021960) and
activating transcription factor 5 (ATF5) (SHCLNV-NM_012068) [27]
were silenced by transduction-ready shRNA lentiviral particles (Sigma-
Aldrich) according to the manufacturer’s instructions. The target sets
included five sequences encoding different small hairpins. The
pLKO.1-puro control transduction particles (SHC001V) did not contain
a hairpin insert and were used as a negative control. Transduction and
selection of stable cells were performed as described previously [26].
Transfection
U87 and LN229 cells were seeded into six-well plates and allowed
to grow overnight until 70% to 80% confluence. Then, cultures were
transfected with myr-AKT1 [Akt1 cDNA (activated) in pUSeamp;
Millipore, Darmstadt, Germany] or with pYN3218-Stat3C [28]
using transfection reagent Metafectene (Biontex, München, Germany)
according to the manufacturer’s instructions. Cells were harvested
48 hours posttransfection for further Western blot analysis.
Immunoblotting
ForWestern blots, cells cultivated in 75-cm2 cell culture flasks were lysed
with SDS lysis buffer including protease and phosphatase inhibitors. Protein
content was quantified with the BC Assay Kit from Uptima (Mannheim,
Germany). Eighty micrograms of protein was loaded onto a 12%
polyacrylamide gel followed by gel electrophoresis. Proteins were transferred
onto nitrocellulose membranes that were incubated with an anti-MCL1,
anti-BAK antibody (S-19, Santa Cruz, Heidelberg, Germany), anti-
pSTAT3 (Tyr705) antibody, anti-AKT antibody, anti-STAT3 antibody,
anti-BAX, anti-BCL2, anti-BCL-XL (all fromCell Signaling, BadHomburg,
Germany), or an anti-GAPDH antibody (Calbiochem, Darmstadt,
Germany). After washing, blots were incubated with a secondary IRDye
800CW goat anti-mouse antibody followed by detection with an Odyssey
Infrared Imaging System (LI-COR, Bad Homburg, Germany).
RNA Isolation and Quantitative Polymerase Chain
Reaction (qPCR)
Cells were cultivated in 75-cm2 cell culture flasks until subconfluency.
RNA isolation was performed by using the RNAeasy Plus Mini Kit
according to themanufacturer’s instructions (Qiagen,Hilden,Germany).
In the procedure, a DNAse digestion step was included. RNA content
was photometrically measured with a BioPhotometer (Eppendorf,
Hamburg, Germany). One microgram of RNA was used for cDNA
synthesis in a 20-μl volume with SuperScript III Reverse Transcriptase
(Invitrogen, Darmstadt, Germany). Quantitative PCR was performed
with the TaqMan Gene Expression Assay using 25 ng of cDNA per
reaction. Analysis was carried out in an ABI PRISM 5700 Sequence
Detection System (Applied Biosystems, Darmstadt, Germany) with the
OneStep Plus Software. Analysis of relative gene expression data was
performed by employing the 2−ΔΔC(t) method.
Caspase 3-Like Enzymatic Activity Assay
For measuring effector caspase activity, treated cells were lysed in
200 μl of lysis buffer [10 mmol/l HEPES (pH 7.4), 42 mmol/l KCl,
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0.1 mmol/l EDTA, 0.1 mmol/l EGTA, 1 mmol/l DTT, 1 μg/mL
pepstatin A, 1 μg/mL leupeptin, 5 μg/mL aprotinin, 0.5% 3-(3-
cholamidopropyldimethylammonio)-1-propane sulfonate (CHAPS)].
Fifty microliters of this lysate was added to 150 μl of reaction buffer
[25 mmol/l HEPES, 1 mmol/l EDTA, 0.1% CHAPS, 10% sucrose,
3 mmol/l DTT (pH 7.5)]. The fluorigenic substrate Ac-DEVD-AMC
was added at a final concentration of 10 μmol/l. Accumulation of AMC
fluorescence was monitored over 2 hours using a TECAN fluorescent
plate reader (Tecan, Crailsheim, Germany; excitation 380 nm, emission
465 nm). Protein content was determined using the Pierce Coomassie
Plus Protein Assay reagent (Fisher Scientific, Schwerte, Germany).
Caspase activity was expressed as a change in fluorescence units per
microgram of protein per hour.
MTT Cell Viability Assay
MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bro-
mide, Sigma Aldrich) working solution (5 mg/ml) was prepared by
dissolving MTT in PBS following sterile filtration. One day before
treatment, 2000 cells/well were plated in a transparent flat-bottom
96-well tissue culture plate in a total volume of 100 μl/well. At least
eight technical replicates were used for each condition. After the
appropriate incubation time, 20 μl of MTT solution was added (final
concentration: 0.83 mg/ml) and incubated for 3 hours at 37°C, 5%
CO2. After carefully removing the medium, 100 μl of 2-propanol was
added to dissolve the formazan salt. Absorbance was measured at 560 nm
with a GENios fluorescence plate reader (Tecan, Mainz, Germany).
Flow Cytometry
For flow cytometric detection, 20,000 cells/well were seeded in
24-well microtiter plates and subjected to the appropriate treatment.
Next, they were washed and trypsinized. Detached cells and
trypsinized adherent cells were collected, pooled, and centrifuged.
The cell pellet was resuspended in 50 μl HEPES buffer (10 mM
Hepes/NaOH, pH 7.4, 140 mM NaCl, 5 mM CaCl2) and stained
with propidium iodide (Sigma-Aldrich) and Annexin V (Roche,
Mannheim, Germany). After a 10-minute incubation, samples were
analyzed in a BD FACS Canto II (BD Biosciences, Heidelberg,
Germany) using FACS Diva Software.
Immunofluorescence Staining for Confocal Microscopy
A total of 20,000 cells/well were plated in a 24-well plate on cover slips
(13 mm) and were allowed to adhere for 24 hours. All treatments were
performed in a final volume of 500 μl. Following treatment, cells were
first washed twice with ice-cold PBS, fixed in 500 μl paraformaldehyde
(4%PFA) for 10 minutes, and permeabilized for 3 minutes with ice-cold
0.1% Triton X-100 in PBS. After subsequent washing steps, unspecific
binding was blocked by 5% horse serum and 0.3% Triton X-100. Anti–
cytochrome c, (BD Pharmingen) was applied in 1% horse serum and
0.3% Triton X-100 in PBS. Afterwards, cells were washed twice with
ice-cold PBS. For secondary antibody incubation. Cy3-conjugated
Donkey Anti-Mouse IgG (Dianova, Hamburg, Germany) was diluted
in 1% horse serum and 0.3% Triton X-100 in PBS, and samples were
incubated while gently shaking at room temperature in the dark and
washed with ice-cold PBS. Cellular nuclei were stained with the
monomeric cyanine nucleic acid stain TO-PRO-3 (Life Technolgies,
Darmstadt, Germany) at a final concentration of 1 μmol/l in PBS for
10 minutes. Images were acquired with a Nikon Eclipse TE2000-S
fluorescencemicroscope coupled to aDS-5Mc cooled color digital camera(Nikon, Düsseldorf, Germany) and NIS Elements AR (version 3.22)
software from Nikon (TO-PRO-3: excitation 642 nm, emission
662 nm; Cy3: excitation 554 nm, emission 568 nm).
Immunoprecipitation
For examination of the activation status of Bax, we employed
immunoprecipitation with μMACS Protein A/G MicroBeads (Miltenyi
Biotec, Bergisch Gladbach, Germany). Briefly, after harvesting and
washing, cells were pelleted and lysed with CHAPS buffer [1% CHAPS
(Sigma), 10 mMHEPES, pH 7.4, 150 mMNaCl], supplemented with
Protease Inhibitor Cocktail (Roche) on ice for 25 minutes followed by
centrifugation at 14,000 rpm for 25 minutes at 4°C. A mouse
monoclonal antibody against active BAX (6A7, Enzo Life Sciences,
Lörrach, Germany) and 50 μl of Protein A/GMicroBeads were added to
500 μg of protein in 400 μl CHAPS buffer, and samples were incubated
under rotation at 4°C overnight. Elution of immune complexes was
performed according to the manufacturers’ protocol (Miltenyi Biotec).
Finally, the eluted precipitates were analyzed by SDS-PAGE with an
anti-BAX antibody and anti-GAPDH antibody.
Statistics
Results are expressed as mean ± SEM. All experiments were
repeated at least three times, yielding similar results. Statistical
analyses were performed using SPSS (IBM, Armonk, NY) with
one-way analysis of variance followed by Tukey’s honestly significant
difference post hoc comparisons. P values b .05 were considered as
statistically significant.
Results
Knockdown of MCL1 and ABT-737–Induced Apoptosis
To analyze the putative role of MCL1 for cell death resistance of
glioma cells, we established a stable lentiviral knockdown of MCL1 in
the two glioblastoma cells lines LN229 and U87 (Figure 1A). The
effect of ABT-737 single-agent treatment (5 μM) was subsequently
assayed by flow cytometric quantification of total cell death in a time
course experiment (4, 8, 16, and 24 hours). Knockdown of MCL1
evoked a significant increase in ABT-737–induced cell death in
LN229 cells (Figure 1B). We also observed a moderate induction of
cell death in MCL1-proficient LN229 wt cells. In LN229 MCL1 KD
cells, ABT-737 induced a transient activation of effector caspases,
peaking at 4 to 8 hours (Figure 1C, left panel). In line with this
observation, an MTT viability assay revealed a significantly lower
MTT activity after treatment with ABT-737 in LN229 MCL1-KD
cells which could be rescued with the pan-caspase-inhibitor zVAD
(Figure 1C, right panel). The potentiating effect of the MCL1
knockdown on ABT-737–induced apoptosis was also confirmed in
U87 cells (Figure 1D). To rule out possible off-target effects of the applied
shRNA, we also transiently knocked down MCL1 with two different
siRNAoligos. In analogy to the data obtainedwith the stable knockdowns
of MCL1, both siRNas significantly enhanced effector caspase activity
and cell death in response to ABT-737 (Suppl. Figure 1, A–C).
Collectively, these data provide evidence that, in glioma cells, MCL1
confers resistance to apoptotic cell death induced by ABT-737.
Synergistic Induction of Apoptosis by Sorafenib and ABT-737
To pharmacologically target MCL1 in wild-type cells, we
employed the multikinase inhibitor sorafenib (final concentration
5 μM), which almost completely depleted protein levels of MCL1 as
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Figure 1. MCL1 knockdown sensitizes glioma cell lines to ABT-737–induced apoptotic cell death. Establishment of a stable lentiviral
MCL1 knockdown in LN229 and U87 glioma cell lines, as determined by Western blotting (A). LN229 control cells (Ø) and MCL1-KD cells
were treated with 5 μM ABT-737 in a time course experiment (4, 8, 16, and 24 hours), and cell death was quantified by FACS analysis of
Annexin/PI (B). Effector caspase activation as determined by DEVD cleavage in LN229 empty vector control cells (Ø) and MCL1-KD cells
after treatment for 1, 2, 4, 8, and 12 hours with 5 μMABT-737 (C, left panel). Analysis of MTT activity in LN229 empty vector control cells
(Ø) and MCL1-KD cells after treatment with 5 μM ABT-737 for 24 hours (C, right panel). Where indicated, cells were additionally treated
with the pan-caspase inhibitor zVAD. U87 control cells (Ø) and MCL1-KD cells were treated with 5 μM ABT-737 in a time course
experiment (4, 8, 16, and 24 hours), and cell death was quantified by FACS analysis of Annexin/PI (D). In all parts of the figure, graphs
represent means of n = 4-8 cultures + SEM. *P b .05, significant difference to untreated controls; #P b .05, significant difference to
respective control cell line.
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detectably affect the expression of the other Bcl-2 family members
BCL-xL, BAK, and BAX but significantly suppressed the expression
of Bcl-2. FACS analysis of Annexin binding/PI uptake confirmed that
LN229 MCL1-KD cells were more sensitive to ABT-737–induced
cell death (Figure 2B), with a prominent shift to Annexin-positive and
Annexin/PI-positive cells that was not seen in the LN229 control cell
line (Figure 2B). Another time course analysis performed after 4, 8,
16, and 24 hours revealed that, whereas sorafenib alone exerted no
effect, the double treatment with ABT-737 and sorafenib efficientlytriggered apoptosis in LN229 control cells (Figure 2, B and C, left
panel) to a level well above ABT-737 alone (compare Figure 1B). This
was associated with enhanced caspase induction (Figure 2C, right
panel). Similar sensitizing effects of sorafenib were also observed in
MCL1-proficient U87 control cells (Figure 2D). The MCL1-KD
evoked an earlier shift to cell death after combined treatment with
ABT-737 and sorafenib in both cell lines (Figure 2, C, left panel, and
D). Single-agent treatment with sorafenib was not sufficient to induce
cell death in LN229 cells under these experimental conditions,
whereas it triggered moderate cell death in U87 control cells and U87
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Western blotting. Western blots were repeated two times with similar results (A). Representative histograms of LN229 control cells (Ø)
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MCL1-KD conditions, sorafenib contributed in both cell lines only
to a minor extent to the profound ABT-737 effects (compare
Figures 2C vs. 1B, 2D vs. 1D), thus confirming that sorafenib acts to a
large extent via suppression of MCL1 in glioma cells.
To confirm activation of apoptotic cell death, we also analyzed
nuclear condensation/fragmentation and mitochondrial cytochrome c
release of LN229 control cells and LN229 MCL1-KD cells after
treatment with sorafenib, ABT-737, and combined treatment with
both drugs on the single-cell level (Figure 3, A and B). In line with
the FACS analyses (Figure 2, B and C), nuclear apoptosis and
cytochrome c release to the cytosol were observed after ABT-737
single-agent treatment in LN229 MCL1-KD cells and after
combined treatment in LN229 control cells, which were further
enhanced in MCL1-KD cells (Figure 3, A and B).
MCL1 Overexpression Is Independent of ATF5
It was previously proposed that the CREB3L2/RAF/ATF5/MCL1
pathway plays a pivotal role in driving the overexpression of MCL1 in
glioma [27]. To further scrutinize the importance of this pathway for
MCL1-driven cell death resistance, we established a stable lentiviral
knockdown of ATF5 in both cell lines (LN229, U87; Figure 4A, left
panel). Unexpectedly, the knockdown of ATF5 had no discernible
effect on basal protein expression levels of MCL1 (Figure 4A, right
panel) as determined by Western blot analysis. qPCR analysis
confirmed that knockdown of ATF5 had no major effects on MCL1
mRNA expression (Figure 4, B and C, left panels), indicating that, in
the two investigated cell models, ATF5 is not a major driver of MCL1
expression and is therefore not involved in the suppressing effects of
sorafenib on MCL1. Of note, sorafenib treatment decreased the
MCL1 mRNA levels in LN229 and U87 cells, indicating that, in
addition to modulating MCL1 protein stability, it also exerts its
suppressing function via inhibition of MCL1 transcription in an
ATF5-independent manner. In analogy to the lack of MCL1
regulation, the ATF5 knockdown also did not alter the extent of
caspase induction after combined treatment with sorafenib and
ABT-737 in both cell lines (Figure 4, B and C, right panels).
Sorafenib Targets MCL1 in a STAT3-Dependent Manner
Given the key function of STAT3 in driving gliomagenesis and
glioma cell death resistance, we next analyzed the possible
involvement of STAT3 in the MCL1-inhibiting effects of sorafenib.
As depicted in Figure 5A, LN229 and U87 glioma cells were treated
with sorafenib or the STAT3 inhibitor WP-1066 [29] for different
time periods. Both drugs were able to reduce levels of MCL1 and
phospho-Stat3 in a time-dependent manner. Next, we investigated
whether a double treatment with WP-1066 and ABT-737 could
mimic the synergizing effects of sorafenib and ABT-737 in LN229
cells (Figure 5B). To this end, LN229 control and MCL1-KD cells
were treated with WP-1066 and ABT-737 for 4, 16, and 24 hours, and
total cell death was subsequently analyzed via flow cytometry after
staining with Annexin V and PI. In analogy to sorafenib, WP-1066 was
able to exert potent synergistic effects with ABT-737 in LN229 control
cells, whereas the MCL1-KD cells revealed a slightly earlier shift to cell
death after the combined treatment (Figure 5B).
To further analyze the mechanisms underlying sorafenib-mediated
MCL1 suppression, a set of transient transfection experiments was
performed to evaluate a possible rescue of MCL1 protein expression
under sorafenib treatment. First, we examined the involvement of theprosurvival kinase AKT, which is known as a downstream target of
sorafenib and an upstream activator of MCL1 [30–32]. For this
purpose, we transfected U87 and LN229 cells with a myristoylated,
constitutively active mutant of AKT1 followed by treatment with
sorafenib. Transient expression of AKT in glioma cells was confirmed
by Western blot analysis showing increased AKT protein levels and
moderately elevated levels of MCL1 in AKT1-transfected cells
compared to mock-transfected controls. However, this pronounced
expression of AKT failed to abrogate the suppressing effect of
sorafenib on MCL1 protein expression when comparing the 4- and
8-hour time points after treatment (Figure 5C).
In light of the synergizing effects of WP-1066 and ABT-737 on cell
death, we also examined the potential effects of a constitutively active
mutant of STAT3 on MCL1 levels. Cells were transfected with the
mutant STAT3-C that does not require tyrosine phosphorylation for its
activation [28], and transient expression of STAT3-C was confirmed by
Western blot. Interestingly, STAT3-C was able to markedly enhance
basal expression levels of MCL1 and to significantly counteract the
suppressing effects of sorafenib on MCL1 4 and 8 hours after drug
application (Figure 5D). Expression of STAT3-C also significantly
reduced cell death induced by ABT-737 in combination with sorafenib
(Suppl. Figure 1,D andE). These results suggest that the STAT3/MCL1
axis is an important target involved in the apoptosis-sensitizing effects of
the multikinase inhibitor sorafenib in glioma.
Discussion
Increasing evidence supports the central function of STAT3 for
gliomagenesis, tumor progression, and therapy resistance of malig-
nant gliomas. STAT3 is known to exert pleiotropic effects on
different tumor cell autonomous functions and the interaction of
tumor cells with the tumor microenvironment. One key oncogenic
property of STAT3 is its antiapoptotic function that is functionally
correlated to the acquired apoptosis resistance of tumor cells. In line
with this notion, inhibition of the Stat3 pathway or constitutively
active Stat3 was shown to induce apoptosis in glioma cells [16,29].
This study was undertaken to investigate the STAT3/MCL1
signaling axis as a target to overcome the resistance of glioma cells to
the BH3 mimetic ABT-737. We have previously demonstrated that
the expression of prosurvival Bcl-2 proteins is correlated with cell
death resistance of glioma cells and that they represent an attractive
target for glioma therapy [26]. The proapoptotic activity of ABT-737
was shown to negatively correlate with MCL1 expression in various
cancer models, and suppression of MCL1 expression was demon-
strated to abrogate ABT-737 resistance in many types of cancer, for
example, in acute myeloid leukemia cells with high endogenous
expression of MCL1 [33]. Therefore, the combination of the orally
applicable ABT-737 derivative ABT-263 with drugs targeting the
expression/stability of MCL1 may be a feasible and elegant approach
for cancer therapies.
To further explore the critical function of MCL1 for apoptosis
resistance of glioma, we performed a stable lentiviral knockdown of
MCL1 that sensitized LN229 and U87 glioma cells to cell death
induced by single treatment with ABT-737. This cell death was
associated with activation of effector caspases, cytochrome c release
from the mitochondria, and nuclear hallmarks of apoptosis.
Concomitantly, combined treatment with ABT-737 and sorafenib,
which we demonstrate to efficiently and quickly reduce MCL1 (and
to a lesser degree Bcl-2) protein levels, was able to exert synergistic
effects on cell death in MCL1-expressing LN229 and U87 cells.
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Figure 3. Detection of apoptosis at the single cell level after treatment with ABT-737 and sorafenib. For analysis on the single cell level,
LN229 control cells (Ø) and LN229 MCL1 knockdown cells were treated with 5 μM ABT-737 or 5 μM sorafenib, or both agents
simultaneously, for 4 hours. After fixation, cells were stained with an anti–cytochrome C antibody. Nuclei were stained with To-Pro (A).
Representative images of apoptotic cells are shown. Scale bar: 10 μm. Experiments were repeated three times with similar results.
Quantitative assessment of cytochrome C release and nuclear condensation/fragmentation (Hoechst staining) by fluorescence
microscopy (B). Data represent means + SEM of 4 independent cultures. One hundred cells were counted for each culture. *P b .05,
significant difference to untreated controls. #P b .05, significant difference to control cell line. Immunoprecipitation of activated BAX in
LN229 control cells and MCL1 KD cells (C). Cells were treated as described above.
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suppression of MCL1 is likely the key mechanism of synergism
between sorafenib and ABT-737. Importantly, the multikinase
inhibitor sorafenib, either alone or in combination with other
drugs, is in clinical development for a wide variety of human cancers
including glioma (https://clinicaltrials.gov). Synergistic effects of
sorafenib with Bcl-2 inhibition were recently also demonstrated for
the orally applicable ABT-737 derivative ABT-263 in cancer cells
[30]. In this context, several groups also proposed that downregu-
lation of MCL1 sensitizes different cancer cell lines to ABT-737 in vitro
[34,35]. This is demonstrated in this study.We next asked the question which upstream signaling components
are essential to drive MCL1 overexpression in glioma. In a previous
report, a CREB3L2/RAF/ATF5 pathway was proposed to be essential
for MCL1 activation and glioma cell survival [27]. Interestingly,
although we demonstrate that sorafenib-dependent suppression of
MCL1 to a large degree occurs at the transcriptional level, our
experiments on the lentiviral knockdown of the transcription
factor ATF5 revealed that MCL1 expression does indeed not depend
on ATF5.
Instead, we found in our experiments an efficient sorafenib-
mediated suppression ofMCL1 expression inMCL1-proficient LN229
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Figure 4. Knockdown of ATF5 has no effect on MCL1 expression and apoptosis sensitivity. Verification of the ATF5 knockdown in LN229
and U87 cells as analyzed by qPCR (A). Two single-cell clones per cell line are shown. Data represent means of n = 3 cultures + SEM;
*P b .05, significant difference to respective control cell line. MCL1 expression of ATF5 knockdown cells in comparison to LN229 control
cells (Ø) as analyzed by Western blotting. GAPDH served as loading control. mRNA levels of MCL1 were assayed by qPCR in control cells
with the corresponding knockdown clones of ATF5 and MCL1 in LN229 (B, left panel) and in U87 (C, left panel) +/− treatment with 5 μM
sorafenib for 24 hours. Data represent means of n = 3 cultures + SEM; *P b .05, significant difference to respective control cell line.
Experiments were repeated three times with similar results. Effector caspase activity after treatment for 4 hours with 5 μM sorafenib,
5 μM ABT-737, or the combination of both (C, D, right panels). Experiments were repeated three times with similar results. All graphs
represent means of n = 4 cultures + SEM; *P b .05, significant difference to untreated controls; #P b .05, significant difference to
respective control cell line. n.s.: not significant.
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activation of STAT3. In line with this, the synergistic effects of
sorafenib and ABT-737 described above could be mimicked in our
experiments by combination of ABT-737 with the STAT3 inhibitor
WP-1066 [29]. Moreover, the constitutively active STAT3 mutant
STAT3-C was able to significantly enhance MCL1 levels, thus
counteracting the effects of sorafenib and retaining cell survival. In
contrast, a constitutively active mutant of AKT failed to sustain
MCL1 expression under sorafenib treatment. These findings are in
line with a study demonstrating sorafenib-dependent downregulation
of pStat3 (Tyr705) and MCL1 expression, whereas the expression of
other apoptosis-related proteins (Bcl-2, Bcl-xL, XIAP, survivin) waslargely unaltered [36]. Another study confirmed the proapoptotic and
STAT3-inhibiting effects of sorafenib and revealed that inactivation
of STAT3 by sorafenib occurs via upstream inhibition of the JAK
kinases JAK1 and JAK2 and increased phosphatase activity in glioma
cells [32], likely involving the participation of the tyrosine
phosphatase SHP2 [37].
Conclusions
Collectively, our data demonstrate that sorafenib targets MCL1 in a
STAT3-dependent manner, thereby sensitizing glioma cells to
treatment with ABT-737. Our results also suggest that targeting
STAT3 in combination with inducers of the intrinsic pathway of
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Figure 5. Treatment with the STAT3 inhibitor WP-1066 reduces MCL1 levels and sensitizes MCL1-KD glioma cells to apoptotic cell death
after combined treatment with ABT-737. LN229 and U87 glioma cells were treated with 10 μM sorafenib or 10 μM WP-1066 for the
indicated time periods and subjected to Western blotting (A). Both drugs reduced MCL1 and phospho-Stat3 expression in a
dose-dependent manner. GAPDH was used as loading control. Quantification of cell death (B). LN229 control or MCL1-KD cells were
treated with 3 μMWP-1066 +/− 5 μM ABT-737 for the indicated time periods. Total cell death was analyzed via Annexin/PI staining and
flow cytometry. Data are means from n = 4 cultures + SEM. Statistical significance: *P b .05 compared to untreated controls; #P b .05
compared to the respective control cell line. Experiments were repeated three times with similar results. Effect of transient
overexpression of constitutively active AKT1 (C) and STAT3 (D) on MCL1 protein levels under treatment with 10 μM sorafenib for the
indicated time periods. Western blot analysis was performed with transfected U87 cells harvested 48 hours posttransfection. GAPDH
was used as loading control. Overexpression of myristoylated AKT1 does not counteract the sorafenib-induced MCL1 downregulation
(C). Increased MCL1 protein expression in cells transfected with STAT3-C in comparison to mock-transfected controls, counteracting
sorafenib-mediated MCL1 inhibition (D).
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malignant glioma.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.neo.2015.07.003.
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